SNTI Stock Overview
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases.
Senti Biosciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.41|
|52 Week High||US$10.35|
|52 Week Low||US$1.20|
|1 Month Change||4.33%|
|3 Month Change||22.34%|
|1 Year Change||-75.85%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-75.85%|
Recent News & Updates
Will Senti Biosciences (NASDAQ:SNTI) Spend Its Cash Wisely?Sep 27
Senti Biosciences initiated at buy at Chardan on gene circuit synthetic biology platformSep 22
Senti Biosciences GAAP EPS of -$0.86, revenue of $1.36MAug 16
|SNTI||US Biotechs||US Market|
Return vs Industry: SNTI underperformed the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: SNTI underperformed the US Market which returned -18.5% over the past year.
|SNTI Average Weekly Movement||39.0%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: SNTI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 39% a week.
Volatility Over Time: SNTI's weekly volatility has increased from 24% to 39% over the past year.
About the Company
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma.
Senti Biosciences, Inc. Fundamentals Summary
|SNTI fundamental statistics|
Is SNTI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SNTI income statement (TTM)|
|Cost of Revenue||US$21.96m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.16|
|Net Profit Margin||-1,014.02%|
How did SNTI perform over the long term?See historical performance and comparison